false
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
Novel Aspects in Incretin and Glucagon Biology: Fr ...
Novel Aspects in Incretin and Glucagon Biology: Fr ...
Novel Aspects in Incretin and Glucagon Biology: From Basic to Clinical Applications
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Summary 1:<br />The video discusses the role of brain plasticity in obesity and metabolic diseases. It focuses on the role of oligodendrocytes and myelin in the brain's plasticity. The speaker presents evidence from studies to show that GPCR signaling in oligodendrocytes regulates their differentiation, survival, and myelin density in the median eminence. They also explore the permeability barrier between the median eminence and the arcuate nucleus and suggest that GPCR signaling in oligodendrocytes may regulate this barrier. The speaker proposes a working model that links oligodendrocyte plasticity and GPCR signaling with the regulation of the permeability barrier and the entry of therapeutic agents into the brain. Overall, this talk provides insights into the role of oligodendrocytes and myelin in brain plasticity and its implications for metabolic homeostasis. No specific credits are mentioned in the summary.<br /><br />Summary 2:<br />The video discusses the development of dual peptide therapies for obesity and type 2 diabetes. It explores different dual peptide combinations such as GLP-1 and glucagon, GLP-1 and GIP, and GLP-1 and amylin. Clinical trial data is presented, showing significant reductions in A1C levels and impressive weight loss in patients with type 2 diabetes and obesity using these dual peptide therapies. The potential for diabetes remission or prevention with dual peptide therapy is also mentioned. Long-term treatment with these medications is emphasized for sustained weight loss. The video concludes by noting the need for further research and clinical trials to optimize dosing and maintenance strategies for dual peptide therapy. No specific credits are mentioned in the summary.
Keywords
brain plasticity
obesity
metabolic diseases
oligodendrocytes
myelin
GPCR signaling
permeability barrier
therapeutic agents
dual peptide therapies
GLP-1
clinical trial data
weight loss
type 2 diabetes
long-term treatment
EndoCareers
|
Contact Us
|
Privacy Policy
|
Terms of Use
CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036
202.971.3636 | 888.363.6274
×